Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
lovastatin · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| lovastatin | DRUG | - |
Inclusion Criteria: * Angiography within 17 weeks of randomization showing patient is at high risk for coronary artery disease but not a candidate for coronary artery graft surgery * Men and women ages 21 through 67 years * Mean plasma cholesterol levels from the first two screening visits in the r...
Top 10 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 7 | PHASE3 | Ziltivekimab, Zenagamtide |
| Amgen Inc. | AMGN | 5 | PHASE3 | Olpasiran, Maridebart cafraglutide |
| Eli Lilly and Company | LLY | 6 | PHASE3 | Lepodisiran, Retatrutide, Muvalaplin, Orforglipron, Clazakizumab |
| Novartis AG Sponsored ADR | NVS | 8 | PHASE3 | Inclisiran, Pelacarsen |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Enlicitide |
| NewAmsterdam Pharma Company N.V. | NAMS | 2 | PHASE3 | Obicetrapib |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Genentech, Inc. | RHHBY | 1 | PHASE2 | Selnoflast |
| Verve Therapeutics, Inc. | VERV | 2 | PHASE2 | VERVE-102 |
Lovastatin is a small molecule drug developed by Merck & Company, Inc. (ticker MRK) for atherosclerosis, a cardiovascular condition. It is an HMGCR inhibitor and has been studied in Phase 2 clinical development. Lovastatin is also known by its ChEMBL identifier CHEMBL503.
Lovastatin is used for atherosclerosis, a condition characterized by hardening and narrowing of the arteries. It has been investigated in a Phase 2 clinical trial called the Monitored Atherosclerosis Regression Study (MARS), which enrolled 270 participants with atherosclerosis and coronary artery disease.
Lovastatin targets HMGCR, also known as HMG-CoA reductase. It acts as an inhibitor of this enzyme. By inhibiting HMGCR, lovastatin interferes with a key step in cholesterol biosynthesis, which is relevant to its development for atherosclerosis.
Lovastatin is developed by Merck & Company, Inc., which trades under the ticker symbol MRK. Merck is the company associated with the clinical development of lovastatin for atherosclerosis.
Lovastatin is in Phase 2 clinical development for atherosclerosis. It is an investigational drug and has not been approved by the FDA for this indication. The Phase 2 trial has been completed.
Lovastatin has been studied in one clinical trial: NCT00116870, titled MARS - Monitored Atherosclerosis Regression Study. This Phase 2 trial was completed, enrolled 270 participants, and was randomized and double-blind. It took place in the United States and included adults aged 21 years and older.